NVO Q4 Earnings Beat Estimates, GLP-1 Drugs Boost Sales, Stock Up
Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes ...
Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 Market Growth
We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
pharmaphorum6d
Catalyst’s rival to NovoSeven hits the mark in phase 2 haemophilia trial
Catalyst Biosciences is a step closer to challenging Novo Nordisk’s NovoSeven in the haemophilia A and B market after reporting positive results in a phase 2 trial. The US biotech’s ...
The Globe and Mail6d
the globe and mail
How much is Novo Nordisk A/S ADR stock worth? Invest with precise valuations. Get Report.